Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases.

ABSTRACT:

Background

Our previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases based on the clinic collected data.

Methods

A total of 282 subjects were divided into healthy controls (HC, n = 47), chronic hepatitis B (CHB, n = 68), HBV-related liver cirrhosis (HBV-LC, n = 167). Soluble CD36 in plasma was measured by ELISA, and monocyte or platelet CD36 expression was determined by flow cytometry.

Results

There was a step-wise increase of sCD36 with the progression of chronic HBV infection, and it was the highest in the HBV- LC

SUBMITTER: Cai C 

PROVIDER: S-EPMC9667018 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature